Nano-haemoglobin-based oxygen carrier increases the radiosensitivity of non-small-cell lung cancer.

Abstract

Haemoglobin-based oxygen carriers (HBOCs) could improve the hypoxic state of non-small-cell lung cancer (NSCLC) and increase radiotherapy sensitivity. We assessed the in vitro effects of nano-HBOC + irradiation therapy (IR) on NSCLC cells and the in vivo effect on a mouse model. H385 human NSCLC cell line was used to evaluate the nano-HBOC effect + IR on the cellular partial pressure of oxygen (pO₂), cell activity and changes in reactive oxygen species (ROS) 1-2 h post-exposure. An NSCLC tumour-bearing mouse model was established to evaluate nano-HBOC+IR efficacy 28 d post-exposure. In vitro, pO₂ tended to increase in nano-HBOC groups versus control, cell activity decreased (p < 0.01) and ROS level increased (p < 0.05). Post-irradiation, pO₂ increased in nano-HBOC+IR groups versus control (p < 0.01), viability decreased (p < 0.01) and ROS increased (p < 0.01). No significant difference between nano-HBOC groups was observed. In vivo, nano-HBOC was most abundant at the tumour site and pO₂ increased 6 h post-injection (p > 0.05). Tumour size was smaller in the IR and nano-HBOC+IR groups versus control. ROS levels and cell death were significantly increased. Nano-HBOC can improve pO₂, enhance radiotherapy's inhibitory ability on NSCLC cell lines and tumour-bearing mouse models, and promote ROS release.